EMBC vs STRO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EMBC shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Mixed signals with both opportunities and risks present.
Sutro Biopharma exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.04, indicating negative shareholders' equity. While the stock has experienced a speculative 1-year price surge of 506.7%, this is fundamentally unsupported by a -21.40% decline in year-over-year revenue and deep operating losses (-288.98% margin). The current price of $31.55 has reached the analyst target mean of $31.44, leaving no projected upside despite the 'buy' recommendation. The combination of shrinking revenue and catastrophic health scores suggests the recent price action is decoupled from fundamental value.
Compare Another Pair
Related Comparisons
EMBC vs STRO: Head-to-Head Comparison
This page compares Embecta Corp. (EMBC) and Sutro Biopharma, Inc. (STRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.